Our Blog

20 September 2019

Do JAK inhibitors have potential in blood and bone marrow cancers?

adult-aging-bottle-1389104 (3)

In a recent survey conducted by Bryter, it was found that six-in-10 hematologists agreed that JAK inhibitors have the potential to be a breakthrough treatment for blood and bone marrow cancers.

This likely stems from the fact that they are an orally administered agent, targeting the JAK-STAT pathway. Aberrant JAK/STAT signaling has been identified to contribute to cancer progression and metastatic development. 

The scientific community is currently investigating which blood and bone marrow cancers could most benefit from JAK inhibitors. So far, potential has been seen in myeloproliferative neoplasms such as myelofibrosis and polycythemia vera.

Toxicity is however a concern. Last year it was found that JAK inhibitors being used to treat myelofibrosis may lead to the development of lymphomas.

Bryter explored the impact of this further in their survey, which revealed that of the 50% of hematologists who were aware of the finding, half reported concern about the toxicity profile/ safety of JAK inhibitors. 

Further details are highlighted in Bryter’s full article, which further explores hematologists’ thoughts on where the best potential for JAK inhibitors lies and any concerns around toxicity that they might have. Click on the link below to download the full results and analysis

Download the Bryter JAK Survey



Related Posts

Unpicking biologics Rx decision-making in psoriasis using Multiple-criteria Decision Analysis (MCDA)

At Bryter Lab, we are always experimenting with new techniques for market research. We’re passionate about providing the...

Read More

8 in 10 UK oncologists agree that the NHS could fall behind the health systems of other developed countries

Advanced cancer treatments are on the horizon, but is the NHS ready?

Read More

So, we need stats to test our pipeline drug - but which technique do we use?

In this blog, Noemi Hahn explains when conjoint is ideal, and when alternative statistical techniques should be consider...

Read More


Bryter is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account .